Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04-03)

被引：0
|
作者：
Wen, P. Y.
Puduvalli, V.
Kuhn, J.
Reid, J.
Cloughesy, T.
Yung, W. A.
Chang, S. M.
Robbins, H. I.
McGovern, R.
Ames, M.
Prados, M. D.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] UT Southwestern, San Antonio, TX USA
[4] Mayo Clin, Rochester, MN USA
[5] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[6] Univ Calif San Francisco, San Francisco, CA 94143 USA
[7] Univ Wisconsin, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2039
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I study of vorinostat (suberoylanilide hydroxamic acid [SAHA]) in combination with temozolomide in patients with malignant gliomas (NABTC 04-03)
    Wen, Patrick
    Puduvalli, Vinay
    Kuhn, John
    Reid, Joel
    Cloughesy, Timothy
    Yung, Wka
    Drappatz, Jan
    Lamborn, Kathleen
    Gilbert, Mark
    Butowski, Nicholas
    Levin, Victor
    Chang, Susan
    Kesari, Santosh
    Robbins, Hi
    McGovern, Renee
    Richon, Victoria
    Frankel, Stanley
    Ames, Matthew
    Zweibel, James
    Prados, Michael
    NEURO-ONCOLOGY, 2007, 9 (04) : 518 - 518
  • [2] Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
    Lee, Eudocia Q.
    Puduvalli, Vinay K.
    Reid, Joel M.
    Kuhn, John G.
    Lamborn, Kathleen R.
    Cloughesy, Timothy F.
    Chang, Susan M.
    Drappatz, Jan
    Yung, W. K. Alfred
    Gilbert, Mark R.
    Robins, H. Ian
    Lieberman, Frank S.
    Lassman, Andrew B.
    McGovern, Renee M.
    Xu, Jihong
    Desideri, Serena
    Ye, Xiabu
    Ames, Matthew M.
    Espinoza-Delgado, Igor
    Prados, Michael D.
    Wen, Patrick Y.
    CLINICAL CANCER RESEARCH, 2012, 18 (21) : 6032 - 6039
  • [3] Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas.
    Wen, P. Y.
    Puduvalli, V. K.
    Kuhn, J. G.
    Reid, J. M.
    Lamborn, K.
    Cloughesy, T. F.
    Chang, S. M.
    Drappatz, J.
    Yung, W. K. A.
    Gilbert, M. R.
    Robins, H. I.
    Lieberman, F. S.
    Lassman, A. B.
    McGovern, R. M.
    Desideri, S.
    Ye, X.
    Ames, M. M.
    Espinoza-Delgado, I. J.
    Grossman, S. A.
    Prados, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Yamada, Yasuhide
    Yamada, Kazuhiko
    Otsuki, Tetsuya
    Kanazu, Shinichi
    Iwasa, Takashi
    Hardwick, James S.
    Tamura, Tomohide
    CANCER SCIENCE, 2009, 100 (09): : 1728 - 1734
  • [5] Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
    Schneider, Bryan J.
    Kalemkerian, Gregory P.
    Bradley, Deborah
    Smith, David C.
    Egorin, Merrill J.
    Daignault, Stephanie
    Dunn, Rodney
    Hussain, Maha
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 249 - 257
  • [6] Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
    Bryan J. Schneider
    Gregory P. Kalemkerian
    Deborah Bradley
    David C. Smith
    Merrill J. Egorin
    Stephanie Daignault
    Rodney Dunn
    Maha Hussain
    Investigational New Drugs, 2012, 30 : 249 - 257
  • [7] Phase I trial of vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with solid tumors
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Yamada, Kazuhiko
    Yamada, Yasuhide
    Koizumi, Fumiaki
    Shimoyama, Tatsu
    Nishio, Kazuto
    Otsuki, Tetsuya
    Frankel, Stanley R.
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S459 - S459
  • [8] A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with gastrointestinal (GI) cancer
    Chin, K.
    Hatake, K.
    Hamaguchi, T.
    Shirao, K.
    Doi, T.
    Noguchi, K.
    Garcia-Vargas, J. E.
    Ohtsu, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Phase I trial of oral vorinostat (Suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma
    Weber, Donna M.
    Jagannath, Sundar
    Mazumder, Amitabha
    Sobecks, Ronald
    Schiller, Gary J.
    Gavino, Maria
    Sumbler, Chantelle
    McFadden, Carrie
    Chen, Cong
    Ricker, Justin L.
    Rizvi, Syed
    Oerth, Carol
    Brownell, Patricia
    Husein, Mohamad A.
    BLOOD, 2007, 110 (11) : 355A - 355A
  • [10] A phase I and pharmacokinetic/pharmacodynamic study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with solid tumor
    Fujiwara, Y.
    Yamamoto, N.
    Yamada, K.
    Yamada, Y.
    Shimoyama, T.
    Koizmi, F.
    Nishio, K.
    Otsuki, T.
    Frankel, S. R.
    Tamura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345